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latter being more aggressive. In the Greater Metropolitan 
Area and Costa Rica in general, free-ranging dogs are com-
mon, including at playgrounds and school yards, sites also 
vulnerable to nocturnal visits by raccoons. Dogs can have 
patent B. procyonis parasite infections and can play a role 
in transmission of the parasite from raccoons to humans.
In Costa Rica, cases of larva migrans have been re-
ported. The Unidad de Investigación y Análisis, Regis-
tros y Estadísticas de Salud at the National Children’s 
Hospital,  San José, Costa Rica, reported 135 cases of 
larva migrans ocularis and 21 cases of visceral larva mi-
grans caused by nonspecifically identified ascarids dur-
ing 2005–2014 (unpub. data). However, these diagnoses 
were based on IgG serologic testing results (Martinez J., 
National Children’s Hospital; pers. comm., 2015), which 
do not identify ascarid species. Western blot testing would 
improve accuracy (10).
The eco-epidemiology of B. procyonis parasites in 
tropical settings is relevant to public health because it might 
play a yet-unrecognized role in larva migrans pathology, 
which can be severe. Increased contact between raccoons 
and humans also warrants further investigation to improve 
understanding and minimize zoonotic risk.
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To the Editor: Artemisinin resistance (ART-R) in 
Plasmodium falciparum phenotypes may have evolved in-
dependently in various areas of the Greater Mekong Sub-
region (1,2), prompting the World Health Organization to 
change its regional policy from containment to elimination 
(3). Risks associated with ART-R include compromised use 
of artemisinin combined therapy, partner drug resistance 
selection, total ART-R resistance, and geographic extension 
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to other malaria-endemic regions (2,3). Characterization of 
ART-R in each setting and rapid update of listed pheno-
types classified as in vitro resistant to this antimalarial drug 
are needed.
Detected in western Cambodia in 2008, ART-R has 
been observed in neighboring countries, notably at the 
Thailand–Myanmar border (4,5). Resistance is partial 
and manifests by an increased parasite clearance half-
life (PCHL) of >5 hours in patients receiving artemisinin 
monotherapy or artemisinin combined therapy (6). In vitro, 
ART-R phenotype has been characterized by the ring-stage 
survival assay (RSA0–3h, cutoff 1%) (7) and mutations in the 
propeller domain of a kelch gene on chromosome 13 (K13) 
(8,9). However, tremendous K13 variability in different ge-
netic backgrounds requires confirmation of specific alleles 
as ART-R markers (2,3); even statistically significant clini-
cal associations are rarely unequivocal (5–9).
On the Thailand–Myanmar border where ART-R has 
been documented (4), we investigated K13 mutations in 
clinical and in vitro phenotypes. Patients with nonsevere 
P. falciparum hyperparasitemia infections treated during 
2011–2013 at the Shoklo Malaria Research Unit (Mae Sot, 
Thailand) were treated with artesunate, then combined 
artesunate/mefloquine (5). We retrospectively selected 33 
case-patients on the basis of PCHL outcome to analyze a 
broad parasite clearance distribution with available cryo-
preserved isolates. Full written consent from all patients 
was obtained. PCHL was calculated on the basis of initial 
and repeated parasitemia measurement every 6 hours until 
undetectable asexual parasitemia (6) was achieved. Venous 
blood samples were cryopreserved before drug administra-
tion (day 0).
Short-term, culture–adapted parasites (3% hemato-
crit; RPMI-1640 supplemented with 10% human serum, 
0.05 mg/mL hypoxanthine, 2 mg/mL sodium bicarbonate, 
2 mg/mL glucose, 0.04 mg/mL gentamicin, 0.3 mg/mL 
L-glutamine in a 37°C candle-jar atmosphere) were split 
for blinded RSA0–3h and K13 genotyping. We performed 
RSA0–3h in duplicate by selecting early rings (0–3 h) in a 
combination of percoll gradient and sorbitol lysis, followed 
by a 6-h exposure to 700 nmol/L dihydroartemisinin (7). 
RSA survival rate was measured microscopically 66 hours 
after drug removal and calculated as the quotient of para-
sitemia upon DHA exposure over control parasitemia with 
dimethyl sulfoxide. Only 25 isolates that were successfully 
culture-adapted provided RSA survival rates.
After the phenotypical assays, the genotypes were ob-
tained and K13 regions were amplified by using 3 primer 
sets: fragment 1 (1725380–1725680 bp, pos 211–302), 
F-tgaaaatatggtaggtgatt and R-atcgtttcctatgttcttct; frag-
ment 2 (1725980–1726520 bp, pos 419–570), F-atc-
taggggtattcaaagg, R-ccaaaagatttaagtgaaag; and fragment 3 
(1726400–1726940 bp, pos 545–707), F-ctgccattcatttgtatct, 
R-ggatatgatggctcttcta) before sequencing (8). The 33 mono-
clonal isolates yielded clear K13 gene sequences. All except 
4 isolates from patients who had PCHL >5 h had a single 
K13 mutant allele (19/23), and all isolates except 1 (G538V) 
from case-patients who had PCHL <5 h carried the K13 3D7 
wild-type allele (9/10). PCHL was significantly different be-
tween K13 wild-type (n = 13, median 4.3 h) and mutant (n 
= 20, median = 7.2 h) alleles (p<0.01 by Mann-Whitney U 
test). Among the 25 isolates successfully tested, RSA sur-
vival rates differed significantly between K13 wild-type (n 
= 10, median 0.5%) and mutant (n = 15, median 3.5%) al-
leles (p<0.001 by Mann-Whitney U test). When PCHL was 
present <5 h, RSA survival rates (n = 7, median 0.5%) were 
significantly lower than when PCHL was >5 hours (n = 18, 
median 3.1%) (p = 0.001 by Mann-Whitney U test).
In detail (Figure), C580Y and N458Y mutants were 
consistently associated with PHCL >5h and RSA values 
>1%. The C580Y allele has been repeatedly confirmed as a 
molecular marker of ART-R (5,7–9). Previous reports have 
inconsistently associated the N458Y mutation with ART-R; 
7 case-patients with PCHL >5 h were reported by Ashley et 
al. (5), and 1 artemisinin sensitive case was reported at the 
China–Myanmar border (10). Nevertheless, this mutation 
has not been confirmed in vitro (3). We confirmed the mu-
tation in vitro, and in vivo, according to the World Health 
Organization definition (3), this K13 allele as a molecular 
marker of ART-R.
Conflicting data observed between PCHL and RSA 
values for 4 mutant alleles (E252Q, P441L, G538V, and 
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Figure. Distribution of parasite clearance half-lives (n = 33, 
squares) and Ring-stage survival assay survival rates (n = 25, 
circles) of Plasmodium falciparum isolates from patients on the 
Thailand–Myanmar border, determined on the basis of each 
K13 genotype. Mean survival rate of duplicate measures are 
showed for each isolate. Dashed line represents the cutoff value 
for parasite clearance half-life (artemisinin resistance >5 h) and 
RSA survival (artemisinin resistance >1%). K13 alleles N458Y 
and C580Y were consistently associated with parasite clearance 
half-life and survival rates above threshold. Bold text indicates 
K13 alleles with variable parasite clearance half-life and RSA 
associations. Horizontal bars represent median values for each 
K13 genotype. Survival rate for laboratory reference 3D7 strain 
was 0.2%.
A675V) require further targeted approaches to relate them 
to previous reports. In a study in which only PCHL were 
reported (5), the proportion of slowly clearing infections 
were 69%, 0%, 30%, and 61% for the P441L, E252Q, 
G538V, and A675V alleles, respectively. Discrepancies can 
result from confounding pharmacologic (drug level, part-
ner drug), immunologic, and parasitologic (genetic back-
ground, parasitic stage at treatment initiation) factors.
RSA results and K13 genotypes were associated with 
delayed parasite clearance, emphasizing the pertinence 
of each method to define ART-R. In this area, N458Y is a 
marker of ART-R. To solve conflicts about specific muta-
tions, more detailed characterization in vitro and in vivo 
is needed.
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To the Editor: We recently reported that postvaccina-
tion serum samples from infants immunized with a novel, 
protein-based multicomponent meningococcal serogroup B 
(MenB) vaccine (Bexsero; GlaxoSmithKline Vaccines, Ve-
rona, Italy) have bactericidal activity against the hyperviru-
lent meningococcal group W (MenW) strain belonging to 
the sequence type (ST) 11 clonal complex (1). Historically, 
MenW has been a rare cause of invasive meningococcal 
disease (IMD), accounting for <5% of confirmed cases in 
England and Wales (2). Since 2009, MenW cases caused by 
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